CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 154 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02777021
NCT02777021N/ACompleted

Home or Away From Home: Comparing Patient and Caregiver Reported Quality of Life (QoL) and Other Patient-centered Outcomes for Inpatient Versus Outpatient Management of Neutropenia in Children With AML

Children's Hospital of Philadelphia·observational·Posted May 19, 2016·Updated Dec 23, 2019

In Brief

An observational study for Pediatric Acute Myeloid Leukemia. Completed, enrolled 154 participants across 15 sites.

Detailed Summary

Treatment for pediatric acute myeloid leukemia (AML) involves intensive chemotherapy regimens that result in periods of profound neutropenia leaving patients susceptible to severe infectious complications. Infectious complications are the leading cause of treatment related mortality among AML patients, but there are little clinical data to inform whether management of neutropenia post AML chemotherapy should occur in an outpatient or inpatient setting. Further, no studies have been conducted that assess the impact of neutropenia management strategy on the quality of life of pediatric patients with AML and their caregivers.

Study Details

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 19, 2016
Enrollment StartSep 1, 2016
Primary CompletionJul 18, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.1 years ago